Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first preclinical candidates for the company’s Ugimer gene-silencing drugs. “We are happy to secure this funding, which gives us the opportunity to build up the Ugimers as a therapeutic gene-silencing product platform in a comprehensive manner,“ said Ugichem CEO Holger Bock. Ugimers are synthetic antisense oligonucleotides that do not require a delivery system to access their target. Ugichem hopes that they will also be able to target cellular compartments that are not accessible through other (RNA) drugs.